semaglutide obesity phase 3 In the OASIS 4 trial, once-daily oral at a dose of 25 mg resulted in a greater mean reduction in body weight than placebo in participants with overweight or Pivotal Results for Semaglutide in

GLP-1 stands for glucagon-like peptide-1 , a hormone your body naturally produces in the gut

Add baseline bloodwork before starting your GLP-1

This side effect is generally transient but should be monitored if: You experience palpitations Theres a noticeable, sustained increase over time Its advisable to have regular cardiac assessments while on GLP-1 medication, especially if you have underlying heart conditions

Black circle added to the green indicates that these synthetic agonists have been slightly modified

Patients with pernicious anemia This autoimmune condition destroys intrinsic factor, the protein required for B12 absorption in the small intestine